Your browser doesn't support javascript.
loading
Progressive deafness-dystonia due to SERAC1 mutations: A study of 67 cases.
Maas, Roeltje R; Iwanicka-Pronicka, Katarzyna; Kalkan Ucar, Sema; Alhaddad, Bader; AlSayed, Moeenaldeen; Al-Owain, Mohammed A; Al-Zaidan, Hamad I; Balasubramaniam, Shanti; Baric, Ivo; Bubshait, Dalal K; Burlina, Alberto; Christodoulou, John; Chung, Wendy K; Colombo, Roberto; Darin, Niklas; Freisinger, Peter; Garcia Silva, Maria Teresa; Grunewald, Stephanie; Haack, Tobias B; van Hasselt, Peter M; Hikmat, Omar; Hörster, Friederike; Isohanni, Pirjo; Ramzan, Khushnooda; Kovacs-Nagy, Reka; Krumina, Zita; Martin-Hernandez, Elena; Mayr, Johannes A; McClean, Patricia; De Meirleir, Linda; Naess, Karin; Ngu, Lock H; Pajdowska, Magdalena; Rahman, Shamima; Riordan, Gillian; Riley, Lisa; Roeben, Benjamin; Rutsch, Frank; Santer, Rene; Schiff, Manuel; Seders, Martine; Sequeira, Silvia; Sperl, Wolfgang; Staufner, Christian; Synofzik, Matthis; Taylor, Robert W; Trubicka, Joanna; Tsiakas, Konstantinos; Unal, Ozlem; Wassmer, Evangeline.
Afiliação
  • Maas RR; Translational Metabolic Laboratory, Department of Laboratory Medicine, Radboud University Medical Center, Nijmegen, the Netherlands.
  • Iwanicka-Pronicka K; Department of Audiology and Phoniatrics, Children's Memorial Health Institute, Warsaw, Poland.
  • Kalkan Ucar S; Division of Metabolic Disease, Ege University Medical Faculty, Department of Pediatrics, Izmir, Turkey.
  • Alhaddad B; Institute of Human Genetics, Technische UniversitätMünchen, Munich, Germany.
  • AlSayed M; Department of Genetics, King Faisal Specialist Hospital and Research Center, Riyadh, Saudi Arabia.
  • Al-Owain MA; Department of Anatomy and Cell Biology, College of Medicine, Alfaisal University, Riyadh, Saudi Arabia.
  • Al-Zaidan HI; Department of Genetics, King Faisal Specialist Hospital and Research Center, Riyadh, Saudi Arabia.
  • Balasubramaniam S; Department of Anatomy and Cell Biology, College of Medicine, Alfaisal University, Riyadh, Saudi Arabia.
  • Baric I; Department of Genetics, King Faisal Specialist Hospital and Research Center, Riyadh, Saudi Arabia.
  • Bubshait DK; Department of Anatomy and Cell Biology, College of Medicine, Alfaisal University, Riyadh, Saudi Arabia.
  • Burlina A; Western Sydney Genetics Program, Children's Hospital at Westmead, Sydney, New South Wales, Australia.
  • Christodoulou J; Discipline of Genetic Medicine & Paediatrics and Child Health, University of Sydney, Sydney, New South Wales, Australia.
  • Chung WK; Department of Pediatrics, University Hospital Center, Zagreb, Croatia.
  • Colombo R; School of Medicine, University of Zagreb, Zagreb, Croatia.
  • Darin N; Department of Pediatrics, College of Medicine, Imam Abdulrahman Bin Faisal University, Dammam, Saudi Arabia.
  • Freisinger P; Division of Inherited Metabolic Diseases, Department of Pediatrics, University Hospital of Padua, Padua, Italy.
  • Garcia Silva MT; Neurodevelopmental Genomics Research Group, Murdoch Children's Research Institute, and Department of Paediatrics, Melbourne Medical School, University of Melbourne, Melbourne, Victoria, Australia.
  • Grunewald S; Genetic Metabolic Disorders Research Unit and Western Sydney Genetics Program, Children's Hospital at Westmead, Sydney, New South Wales, Australia.
  • Haack TB; Discipline of Child and Adolescent Health and Genetic Medicine, Sydney Medical School, University of Sydney, Sydney, New South Wales, Australia.
  • van Hasselt PM; Departments of Pediatrics and Medicine, Columbia University, New York, NY.
  • Hikmat O; Institute of Clinical Biochemistry, Faculty of Medicine, Catholic University of the Sacred Heart, Rome, Italy.
  • Hörster F; Center for the Study of Rare Hereditary Diseases, Niguarda Ca' Granda Metropolitan Hospital, Milan, Italy.
  • Isohanni P; Department of Pediatrics, Institute of Clinical Sciences, University of Gothenburg, Queen Silvia's Children's Hospital, Gothenburg, Sweden.
  • Ramzan K; Childrens Hospital, Klinikum Reutlingen, Reutlingen, Germany.
  • Kovacs-Nagy R; Inborn Errors of Metabolism and Mitochondrial Disease Unit, "12 de Octubre" University Hospital, Avenida de Cordoba sn, 28041 Madrid, Spain. Rare Diseases Biomedical Research Centre (CIBERER), Madrid, Spain.
  • Krumina Z; Complutense University, Madrid, Spain.
  • Martin-Hernandez E; Metabolic Medicine Department, Great Ormond Street Hospital for Children National Health Service Foundation Trust, University College London Institute of Child Health, London, United Kingdom.
  • Mayr JA; Institute of Human Genetics, Technische UniversitätMünchen, Munich, Germany.
  • McClean P; Institute of Medical Genetics and Applied Genomics, Tübingen, Germany.
  • De Meirleir L; Wilhelmina Children's Hospital Utrecht, University Medical Center Utrecht, Utrecht, the Netherlands.
  • Naess K; Department of Pediatrics, Haukeland University Hospital, Bergen, Norway.
  • Ngu LH; Department of Clinical Medicine (K1), University of Bergen, Bergen, Norway.
  • Pajdowska M; Department of General Pediatrics, Division of Neuropediatrics and Pediatric Metabolic Medicine, University Hospital Heidelberg, Heidelberg, Germany.
  • Rahman S; Children's Hospital, University of Helsinki and Helsinki University Hospital, Helsinki, Finland.
  • Riordan G; Research Programs Unit, Molecular Neurology, Biomedicum Helsinki, University of Helsinki, Helsinki, Finland.
  • Riley L; Department of Genetics, King Faisal Specialist Hospital and Research Center, Riyadh, Saudi Arabia.
  • Roeben B; Department of Anatomy and Cell Biology, College of Medicine, Alfaisal University, Riyadh, Saudi Arabia.
  • Rutsch F; Institute of Human Genetics, Technische UniversitätMünchen, Munich, Germany.
  • Santer R; Department of Biology and Microbiology, Riga Stradin's University, Riga, Latvia.
  • Schiff M; Inborn Errors of Metabolism and Mitochondrial Disease Unit, "12 de Octubre" University Hospital, Avenida de Cordoba sn, 28041 Madrid, Spain. Rare Diseases Biomedical Research Centre (CIBERER), Madrid, Spain.
  • Seders M; Complutense University, Madrid, Spain.
  • Sequeira S; Department of Pediatrics, Salzburg State Hospitals and Paracelsus Medical University, Salzburg, Austria.
  • Sperl W; Leeds Teaching Hospitals National Health Service Trust, Leeds, United Kingdom.
  • Staufner C; Pediatric Neurology, Brussels University Hospital, Brussels, Belgium.
  • Synofzik M; Department of Pediatric Neurology, Karolinska University Hospital, Stockholm, Sweden.
  • Taylor RW; Division of Clinical Genetics, Department of Genetics, Kuala Lumpur Hospital, Kuala Lumpur, Malaysia.
  • Trubicka J; Department of Clinical Biochemistry, Radioimmunology, and Experimental Medicine, Children's Memorial Health Institute, Warsaw, Poland.
  • Tsiakas K; University College London Great Ormond Street Institute of Child Health, London, United Kingdom.
  • Unal O; Department of Pediatric Neurology, Red Cross War Memorial Children's Hospital, Cape Town, South Africa.
  • Wassmer E; Genetic Metabolic Disorders Research Unit and Western Sydney Genetics Program, Children's Hospital at Westmead, Sydney, New South Wales, Australia.
Ann Neurol ; 82(6): 1004-1015, 2017 Dec.
Article em En | MEDLINE | ID: mdl-29205472
ABSTRACT

OBJECTIVE:

3-Methylglutaconic aciduria, dystonia-deafness, hepatopathy, encephalopathy, Leigh-like syndrome (MEGDHEL) syndrome is caused by biallelic variants in SERAC1.

METHODS:

This multicenter study addressed the course of disease for each organ system. Metabolic, neuroradiological, and genetic findings are reported.

RESULTS:

Sixty-seven individuals (39 previously unreported) from 59 families were included (age range = 5 days-33.4 years, median age = 9 years). A total of 41 different SERAC1 variants were identified, including 20 that have not been reported before. With the exception of 2 families with a milder phenotype, all affected individuals showed a strikingly homogeneous phenotype and time course. Severe, reversible neonatal liver dysfunction and hypoglycemia were seen in >40% of all cases. Starting at a median age of 6 months, muscular hypotonia (91%) was seen, followed by progressive spasticity (82%, median onset = 15 months) and dystonia (82%, 18 months). The majority of affected individuals never learned to walk (68%). Seventy-nine percent suffered hearing loss, 58% never learned to speak, and nearly all had significant intellectual disability (88%). Magnetic resonance imaging features were accordingly homogenous, with bilateral basal ganglia involvement (98%); the characteristic "putaminal eye" was seen in 53%. The urinary marker 3-methylglutaconic aciduria was present in virtually all patients (98%). Supportive treatment focused on spasticity and drooling, and was effective in the individuals treated; hearing aids or cochlear implants did not improve communication skills.

INTERPRETATION:

MEGDHEL syndrome is a progressive deafness-dystonia syndrome with frequent and reversible neonatal liver involvement and a strikingly homogenous course of disease. Ann Neurol 2017;821004-1015.
Assuntos

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Hidrolases de Éster Carboxílico / Atrofia Óptica / Progressão da Doença / Distonia / Surdocegueira / Deficiência Intelectual / Mutação Tipo de estudo: Clinical_trials / Etiology_studies / Incidence_studies / Observational_studies / Prognostic_studies / Risk_factors_studies Limite: Adolescent / Adult / Child / Child, preschool / Female / Humans / Infant / Male / Newborn Idioma: En Ano de publicação: 2017 Tipo de documento: Article

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Hidrolases de Éster Carboxílico / Atrofia Óptica / Progressão da Doença / Distonia / Surdocegueira / Deficiência Intelectual / Mutação Tipo de estudo: Clinical_trials / Etiology_studies / Incidence_studies / Observational_studies / Prognostic_studies / Risk_factors_studies Limite: Adolescent / Adult / Child / Child, preschool / Female / Humans / Infant / Male / Newborn Idioma: En Ano de publicação: 2017 Tipo de documento: Article